

EMA/145135/2018

European Medicines Agency decision

P/0102/2018

of 16 March 2018

on the acceptance of a modification of an agreed paediatric investigation plan for quizartinib (EMA-001821-PIP01-15-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0102/2018

of 16 March 2018

on the acceptance of a modification of an agreed paediatric investigation plan for quizartinib (EMA-001821-PIP01-15-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0203/2016 issued on 22 July 2016,

Having regard to the application submitted by Daiichi Sankyo Europe GmbH on 29 November 2017 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 23 February 2018, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for quizartinib, film-coated tablet, powder for oral solution, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Daiichi Sankyo Europe GmbH, Zielstattstrasse 48, 81379 – Munich, Germany.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/811964/2017

London, 23 February 2018

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001821-PIP01-15-M01

Scope of the application

Active substance(s):

Quizartinib

Condition(s):

Treatment of acute myeloid leukaemia

Pharmaceutical form(s):

Film-coated tablet

Powder for oral solution

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Daiichi Sankyo Europe GmbH

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Daiichi Sankyo Europe GmbH submitted to the European Medicines Agency on 29 November 2017 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0203/2016 issued on 22 July 2016.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 3 January 2018.



Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of acute myeloid leukaemia

The waiver applies to:

- the paediatric population from birth to less than 1 month of age;
- film-coated tablet, powder for oral solution, oral use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition

Treatment of acute myeloid leukaemia

2.1.1. Indication(s) targeted by the PIP

- For the treatment of paediatric patients aged from 1 month to less than 18 years of age with refractory or relapsed AML with FLT3-ITD mutations after failure of front line intensive chemotherapy regimen, in combination with standard chemotherapy.
- For the treatment of paediatric patients aged from 1 month to less than 18 years of age with newly diagnosed AML with FLT3-ITD mutations.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 month to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Powder for oral solution

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	2	Study 1 Dose range-finding juvenile toxicity study. Study 2 Juvenile toxicity study.

Clinical studies	2	Study 3 Open-label, single-arm trial to evaluate safety, pharmacokinetics, pharmacodynamics and efficacy of quizartinib in combination with FLA/DNX chemotherapy, with optional consolidation therapy, and as single-agent after high-dose therapy in paediatric patients with FLT3-ITD AML from 1 month to less than 18 years of age (and young adults), with expansion cohort. Study 4 Open-label, single-arm trial to evaluate safety, pharmacokinetics, pharmacodynamics and activity of quizartinib in combination with ADE chemotherapy and as single-agent after high-dose therapy in paediatric patients newly-diagnosed with FLT3-ITD AML from 1 month to less than 18 years of age (and young adults).
Extrapolation, modelling and simulation studies	1	Study 5 Exposure-response model.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By June 2023
Deferral for one or more measures contained in the paediatric investigation plan:	Yes